Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones, which include, corticosteroids: which gauge the body's response to illness or injury; mineralocorticoids: which regulate salt and water levels; and androgens: which are male sex hormones.
Congenital Adrenal Hyperplasia Market key facts
According to the Orphanet, the prevalence of Congenital Adrenal Hyperplasia is estimated to be 1–9 /100,000 cases.
After birth, all newborns in the United States are screened for a variety of conditions, including 21-hydroxylase deficiency. This is the most common cause of congenital adrenal hyperplasia (CAH) and accounts for 95% of classic Congenital Adrenal Hyperplasia cases. Nonclassic CAH is not detected through newborn screening and is often not suspected until signs and symptoms of the condition begin to appear later in childhood or early adulthood.
DelveInsight's "Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Congenital Adrenal Hyperplasia Market, historical and forecasted epidemiology, the pipeline insight as well as the Congenital Adrenal Hyperplasia market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Congenital Adrenal Hyperplasia Market Size and Growth Analysis
The Congenital Adrenal Hyperplasia market size shall increase during the forecast period, owing to the launch of upcoming therapies.
The Congenital Adrenal Hyperplasia market analysis section of the report helps to build the detailed comprehension of the historic, current and forecasted Congenital Adrenal Hyperplasia market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Congenital Adrenal Hyperplasia market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Congenital Adrenal Hyperplasia Epidemiology Forecast
The Congenital Adrenal Hyperplasia epidemiology section covers insights about historical and current Congenital Adrenal Hyperplasia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Congenital Adrenal Hyperplasia Pipeline Analysis and Key Companies
The Congenital Adrenal Hyperplasia Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to get launched in the market during the study period. The analysis covers the Congenital Adrenal Hyperplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.
The dynamics of the congenital adrenal hyperplasia (CAH) market is anticipated to change during the forecast period, owing to the expected launch of emerging therapies during the forecast period.
Some of the Key Congenital Adrenal Hyperplasia (CAH) companies include:
Neurocrine Biosciences
Spruce Biosciences
Diurnal
Milendo Therapeutics
And many others.